• 1
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:14515.
  • 2
    Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990;11:578610.
  • 3
    Jordan VC, Gottardis MM, Satyaswaroop PG. Tamoxifen-stimulated growth of human endometrial carcinoma. Ann N Y Acad Sci 1991;622:43946.
  • 4
    Cohen I, Rosen DJD, Altaras M, Beyth Y, Shapira J, Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations, and fibroid overgrowth. Br J Cancer 1994;69:6201.
  • 5
    Sonnendecker HEM, Cooper K, Kalian KN. Primary fallopian tube adenocarcinoma in situ associated with adjuvant tamoxifen therapy for breast carcinoma. Gynecol Oncol 1994;52:4027.
  • 6
    Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:137188.
  • 7
    Seidman JD, Kurman RJ. Tamoxifen and endometrium. Int J Gynecol Pathol 1999;18:2935.
  • 8
    Bernstein L, Deapen D, Cerhan JR. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:16547.
  • 9
    Van Leeuwen FE, Bergman L, Benraadt J. Does risk of endometrial cancer increase with longer duration of tamoxifen use? Eur J Cancer 1998;34:445.
  • 10
    Fisher B, Constantino JP, Redmond CK et al. Endometrial cancer in tamoxifen treated breast cancer patients; findings from the NSABP B 14. J Natl Cancer Inst 1994;86:52737.
  • 11
    Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;333:11720.
  • 12
    Rutqvist LE, Johansson H, Signomklao T et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:64551.
  • 13
    Silva EG, Tornos CS, Mitchell MF. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma. The effects of tamoxifen. Int J Gynecol Pathol 1994;13:24853.
  • 14
    Deligdisch L, Kalir T, Cohen CJ. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000;78:1814.
  • 15
    Mourits MJ, Hollema H, De Vries EG, Ten Hoor KA, Willemse PH, Van Der Zee AG. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol 2002;33:3416.
  • 16
    Holtz D, Ramondetta LM, Burke TW et al. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res 2002;22:29458.
  • 17
    Kazandi M, Sendag F, Akercan F, Terek MC. Ovarian cysts in postmenopausal tamoxifen-treated breast cancer patients with endometrial thickening detected by transvaginal sonography. Eur J Gynaecol Oncol 2002;23:2579.
  • 18
    Seoud M, Salem Z, Shamseddine A, Khabbaz A, Zaatari G, Khalil A. Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment. Eur J Gynaecol Oncol 1999;20:2379.
  • 19
    Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol 2005;35:60711.
  • 20
    Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:45662.
  • 21
    Metcalfe KA, Lynchc HT, Ghadiriand P et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;96:2226.
  • 22
    Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res 1994;14:6038.
  • 23
    Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:3016.
  • 24
    Chen Y, Zheng H, Yang X, Sun L, Xin Y. Effects of mutation and expression of PTEN gene mRNA on tumorigenesis and progression of epithelial ovarian cancer. Chin Med Sci J 2004;19:2530.
  • 25
    Lee JS, Choi YD, Choi C, Lee MC, Park CS, Min KW. Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. Anal Quant Cytol Histol 2005;27:20210.
  • 26
    Leng Y, Yang B, Cao L, Gu ZP. Effects of anordrin, droloxifene, nomegrstrol, and mifepristone on cultured rat luteal cell apoptosis. Acta Pharmacol Sin 1999;20:4004.